gestern wieder wieder ein gewaltige Plus. Nach Börsenschluss kamen die News.
Bin schon auf heute gespannt.
Press Release Source: Grant Life Sciences
Grant Life Sciences hires Kim Liao as Director of Asian Business Development Wednesday December 6, 1:50 pm ET Previously held senior executive positions with Abbott Laboratories Service Corp.'s Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide (Taiwan)
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences ('Grant') Inc. (OTC BB: GLIF - News) announced today that it has hired Mr. Kim Liao as director of Asian business development, effective immediately. ADVERTISEMENT
"We are extremely pleased to have such an accomplished industry executive as Kim Liao join Grant Life Sciences, particularly in light of his significant 'hands on' experience in the markets of Taiwan, China and Singapore," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "Certainly, Kim will play a key role in executing Grant's new corporate strategy: (1) acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels. Kim will oversee development of Grant's expansion into Asia, including the structuring of clinical trials for our HPV-DNA tests at United Clinical Lab (the largest reference lab in Taiwan} and National Taiwan University's Medical Center. In short, Kim will be spearheading the commercialization of Grant's products from clinical acceptance to sales in new, key Asian markets."
Between 1995 and 2006, Kim Liao held a variety of executive positions with increasing responsibilities in the areas of sales, product management and general management with Abbott Laboratories Services Corp.'s Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide (Taiwan). He holds a master's degree in microbiology from California State University (Fullerton) as well as numerous certifications in pathology and clinical laboratory technology.
About Grant Life Sciences Inc.
Grant Life Sciences, a development stage company, engages in research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact: Grant Life Sciences Inc. Don Rutherford, CFO, 949-521-1232
|